Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review
Issued Date
2025-01-01
Resource Type
eISSN
26740826
Scopus ID
2-s2.0-105002477688
Journal Title
Frontiers in Ophthalmology
Volume
5
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Ophthalmology Vol.5 (2025)
Suggested Citation
Stamer W.D., Chiu T., Lu D.W., Wang T.H., Rojanapongpun P., Ruangvaravate N., Jo Y.H., Moster M.R., Fingeret M., Cothran N.L., Steen J., Gaddie I.B., Uçakhan-Gündüz Ö., Shamseldin Shalaby W., Hutnik C.M.L. Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. Frontiers in Ophthalmology Vol.5 (2025). doi:10.3389/fopht.2025.1554777 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/109653
Title
Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review
Author's Affiliation
Siriraj Hospital
Konkuk University Medical Center
National Taiwan University Hospital
Sidney Kimmel Medical College
SUNY College of Optometry
Wills Eye Hospital
King Chulalongkorn Memorial Hospital
Nova Southeastern University
Ankara Üniversitesi
Triservice General Hospital Taiwan
Western University
Duke Eye Center
Chinese University of Hong Kong
Faculty of Medicine
Gaddie Eye Centers
Eye Institute of West Florida
Konkuk University Medical Center
National Taiwan University Hospital
Sidney Kimmel Medical College
SUNY College of Optometry
Wills Eye Hospital
King Chulalongkorn Memorial Hospital
Nova Southeastern University
Ankara Üniversitesi
Triservice General Hospital Taiwan
Western University
Duke Eye Center
Chinese University of Hong Kong
Faculty of Medicine
Gaddie Eye Centers
Eye Institute of West Florida
Corresponding Author(s)
Other Contributor(s)
Abstract
Latanoprostene bunod ophthalmic solution (LBN) 0.024% is a topical nitric oxide (NO)-donating prostaglandin F2α (PGF2α) analog first approved in November 2017 for reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). This narrative review describes the unique mechanism of action of LBN and summarizes available real-world data. Upon instillation, LBN is metabolized into latanoprost acid and butanediol mononitrate, which is further reduced to NO and an inactive metabolite. Latanoprost acid increases aqueous humor outflow primarily through the uveoscleral (unconventional) pathway, whereas NO increases outflow through the trabecular (conventional) pathway. Eight studies were identified: 2 studies in newly diagnosed, treatment-naïve patients with OHT or OAG, 4 studies of adjunctive therapy in patients with glaucoma receiving other IOP-lowering therapies, and 2 studies in which patients with glaucoma switched to LBN monotherapy or adjunctive therapy. Decreases in IOP after initiating LBN in newly diagnosed patients or adding/switching to LBN were generally consistent with reductions observed in clinical trials and sustained throughout the studies. Rates of discontinuation due to inadequate IOP lowering ranged from 12.2% to 17.1%. LBN was generally well tolerated in real-world studies; the most common adverse events were consistent with the known safety profile of LBN. Data from real-world studies provide important insights regarding the potential effectiveness and tolerability of LBN in the clinical setting and suggest that LBN is well tolerated and associated with significant, clinically meaningful, and durable reductions in IOP.